A novel lncRNA‐miRNA‐mRNA network analysis identified the hub lncRNA RP11‐159F24.1 in the pathogenesis of papillary thyroid cancer

Jiang, Wei; Zhan, Hong; Jiao, Yanyan; Li, Sha; Gao, Weixu

doi:10.1002/cam4.1900

Cited by 9 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MicroRNAs are small noncoding RNAs which could negatively regulate the expression of the target genes by directly binding their 3′-UTRs [24]. It has been found that the deregulation of miRNA expression is a common feature of many types of human cancers, including thyroid cancer [25,26]. Accumulated evidence has demonstrated that the aberrant expression of miRNAs plays crucial roles in cancer initiation and progression [27][28][29][30].…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‐384 Inhibits the Progression of Papillary Thyroid Cancer by Targeting PRKACB

Wang

Zhou

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. Growing evidence shows that dysregulation of miRNAs plays a significant role in papillary thyroid cancer (PTC) tumorigenesis and development. The abnormal expression of miR-384 has been acknowledged in the proliferation or metastasis of some cancers. However, the function and the underlying mechanism of miR-384 in PTC progression remain largely unknown. Methods. Real-time PCR was conducted to detect miR-384 expression in 58 cases of PTC and their adjacent noncancerous tissues. MTT, soft agar assay Transwell assay, and wound-healing assay were carried out to explore the biological function of miR-384 in PTC cell lines of BCPAP and K1. Bioinformatics analysis, dual-luciferase reporter assay, western blot, and functional complementation analysis were conducted to explore the target gene of miR-384. Moreover, Spearman’s correlation analysis was conducted to reveal the correlation between miR-384 and PRKACB mRNA in PTC. Results. The expression of miR-384 decreased obviously in PTC, especially in the tumors with lymph node metastasis or larger tumor size. The ectopic upregulation of miR-384 significantly suppressed PTC progression, and the inhibition of miR-384 had the opposite effects. Moreover, PRKACB gene was confirmed as the target of miR-384. Conclusion. The study suggests that miR-384 serves as a tumor suppressor in PTC progression by directly targeting the 3′-UTR of PRKACB gene.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA‐384 Inhibits the Progression of Papillary Thyroid Cancer by Targeting PRKACB

Wang

Zhou

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…miR-485 showed a significantly lower expression in PTC tissues as compared with normal tissues (26). As the targets of miR-485, 47 mRNAs were associated with several biological processes, especially pathways in cancer.…”

Section: :1 119 Clinical Studymentioning

confidence: 96%

Identification of exosomal miRNA biomarkers for diagnosis of papillary thyroid cancer by small RNA sequencing

Dai

Tan

Guo

et al. 2020

European Journal of Endocrinology

View full text Add to dashboard Cite

Context Exosomal miRNAs are considered potential non-invasive biomarkers for thyroid cancer. However, the global exosomal miRNAs profile for papillary thyroid cancer (PTC) has not been revealed. Objective This study investigated the diagnostic value of plasma and serum exosomal miRNAs for PTC. Methods Plasma and serum samples were collected from ten patients with benign thyroid nodules and 17 with PTC for small RNA sequencing. Plasma samples were collected from two independent cohorts, including 119 patients with PTC, 51 healthy people and 82 patients with benign thyroid nodules, for validation by quantitative reverse-transcription polymerase chain reaction (RT-qPCR). Results Small RNA sequencing identified 41 putative exosomal miRNA biomarkers for PTC. Twelve miRNAs were selected for validation. miR-376a-3p, miR-4306, miR-4433a-5p, and miR-485-3p expression significantly increased in patients with PTC compared to that in healthy people and patients with benign thyroid nodules (P ˂ 0.05). Moreover, miR-485-3p and miR-4433a-5p presented larger areas under the curve (AUCs). The high expression of exosomal miR-485-3p correlated with tumor size greater than or equal to 1 cm, advanced clinical stage, extrathyroidal extension, BRAF mutation, and lymph node metastasis. Besides, miR-485-3p exhibited the highest AUCs in diagnosing PTC patients with high-risk factors. Conclusions Plasma exosomal miR-485-3p and miR-4433a-5p might serve as biomarkers for PTC diagnosis. Plasma exosomal miR-485-3p could enable discrimination between high-risk and low-risk PTC.

show abstract

“…It was recently reported that overexpression of MALAT1 could sponge miR-429 and regulate cervical cancer pathogenesis in vivo and in vitro (54), while the associations between MALAT1 and RUNX3 remain unclear. However, the role of RP11-54O7.3 has not yet been fully elucidated, and the association between RP11-54O7.3 and RUNX3 remains unknown (55,56). These results indicate that RUNX3 may affect the expression of lncRNAs , which may be associated with cervical cancer in vitro .…”

Section: Discussionmentioning

confidence: 99%

Transcriptome changes induced by RUNX3 in cervical cancer cells in�vitro

Gao

Zhou

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Runt-related transcription factor 3 (RUNX3) is a member of Runt domain family that is known to play key roles in various different types of tumor. It was recently demonstrated that RUNX3 may also be associated with cervical cancer. The aim of the present study was to investigate the potential association between transcriptome changes and RUNX3 expression in cervical cancer. A RUNX3 overexpression model was constructed using cervical cancer cell lines by RUNX3 plasmid transfection. It was demonstrated that the upregulated expression of RUNX3 inhibited proliferation of cervical cancer cell lines, particularly SiHa cells, and was associated with the expression of the IL-6, PTGS2, FOSL1 and TNF genes. In addition, it was revealed that the TNF and FoxO pathways may also be affected by RUNX3. Therefore, the expression of the RUNX3 gene may be involved in the occurrence and progression of cervical cancer.

show abstract

A novel lncRNA‐miRNA‐mRNA network analysis identified the hub lncRNA RP11‐159F24.1 in the pathogenesis of papillary thyroid cancer

Cited by 9 publications

References 31 publications

MicroRNA‐384 Inhibits the Progression of Papillary Thyroid Cancer by Targeting PRKACB

MicroRNA‐384 Inhibits the Progression of Papillary Thyroid Cancer by Targeting PRKACB

Identification of exosomal miRNA biomarkers for diagnosis of papillary thyroid cancer by small RNA sequencing

Transcriptome changes induced by RUNX3 in cervical cancer cells in�vitro

Contact Info

Product

Resources

About